Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesCash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesFree Cash FlowNet Cash FlowNet IncomeOther Working Capital Changes
Growth Metrics
Income Statement
Others
Ratios

Regen BioPharma (RGBPP) Change in Account Payables (2016 - 2025)

Historic Change in Account Payables for Regen BioPharma (RGBPP) over the last 13 years, with Q4 2025 value amounting to -$31640.0.

  • Regen BioPharma's Change in Account Payables changed 0.0% to -$31640.0 in Q4 2025 from the same period last year, while for Dec 2025 it was -$126560.0, marking a year-over-year change of 0.0%. This contributed to the annual value of -$126560.0 for FY2025, which is 1067.63% up from last year.
  • Per Regen BioPharma's latest filing, its Change in Account Payables stood at -$31640.0 for Q4 2025, which was down 0.0% from -$31640.0 recorded in Q3 2025.
  • Regen BioPharma's 5-year Change in Account Payables high stood at $1.9 million for Q2 2021, and its period low was -$59210.0 during Q4 2021.
  • Over the past 5 years, Regen BioPharma's median Change in Account Payables value was -$31640.0 (recorded in 2022), while the average stood at $65180.0.
  • Examining YoY changes over the last 5 years, Regen BioPharma's Change in Account Payables showed a top increase of 6689458.78% in 2021 and a maximum decrease of 185749.48% in 2021.
  • Quarter analysis of 5 years shows Regen BioPharma's Change in Account Payables stood at -$59210.0 in 2021, then surged by 46.56% to -$31640.0 in 2022, then crashed by 47.81% to -$46767.0 in 2023, then soared by 32.35% to -$31640.0 in 2024, then changed by 0.0% to -$31640.0 in 2025.
  • Its Change in Account Payables stands at -$31640.0 for Q4 2025, versus -$31640.0 for Q3 2025 and -$31640.0 for Q2 2025.